Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening a new family of biological assays capable to simultaneously quantify clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms, , Thrombotargets is continuously creating a novel and promising pipeline of drug candidates.

       

 

 

 

 

 
 
 
   
News
Thrombotargets Corp and KBI Biopharma announce GMP Phase I/II Manufacturing Contract for TT-103MH
• Thrombotargets presents the new products' pipeline during the investors´ annual meeting 2008.
• Thrombotargets receives the “Premi Ciutat de Barcelona” award 2007.
Upcoming events
• Thrombotargets Corp. will attend BIO-Europe Spring® 2008, the International Partnering Conference, Madrid, Spain, 2008.

Pipeline

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.


Contact Us
Site Map
Privacy
Terms of Use
© 2006 - Thrombotargets Corp. All rights reserved - Coagulation - Hemostatic